Low Systemic Inflammation Response Index Predicts Good Prognosis in Locally Advanced Pancreatic Carcinoma Patients Treated with Concurrent Chemoradiotherapy
Table 1
Baseline patient and disease characteristics.
Characteristics
All patients ()
SIRI <1.6 ()
SIRI ≥1.6 ()
value
Median age, years (range)
57 (29-79)
55 (31-79)
58 (29-78)
0.86
Age group (; %)
<70 years
121 (78.6)
44 (75.9)
77 (80.2)
0.21
≥70 years
33 (21.4)
14 (24.1)
19 (19.8)
Gender (; %)
Female
34 (22.1)
13 (23.4)
21 (21.9)
0.85
Male
120 (77.9)
45 (77.6)
75 (78.1)
ECOG performance (; %)
0
62 (40.2)
22 (37.9)
40 (41.7)
0.69
1
92 (59.8)
36 (62.1)
56 (58.3)
Tumor location (; %)
Head
124 (80.5)
47 (81.0)
77 (80.2)
0.92
Body/tail
30 (19.5)
11 (19.0)
19 (19.8)
N-stage (; %)
0
81 (52.6)
30 (51.7)
51 (53.1)
0.77
1
73 (47.4)
28 (48.3)
45 (46.9)
CA 19-9 (; %)
≤90 U/mL
48 (31.2)
21 (36.2)
27 (28.1)
0.18
>90 U/mL
106 (68.8)
37 (63.8)
69 (71.9)
Median neutrophils (103/mm3)
4.21
3.53
5.84
0.001
Median M/L
0.38
0.34
0.44
0.002
Abbreviations: ALI: advanced lung cancer inflammation index; ECOG: Eastern Cooperative Oncology Group; N-stage: nodal stage; CA 19-9: cancer antigen 19-9; BMI: body mass index; M/L: monocyte/lymphocyte.
